NCT00300612 - Vaccine Treatment for Advanced Malignant Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL

HyperAcute-Melanoma Vaccine

Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa